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Abstract
Background: The focus of Chlamydia trachomatis screening and testing lies more on women than on men. The
study aim was to establish by systematic review the prevalence of urogenital Chlamydia trachomatis infection in
men and women in the general population.
Methods: Electronic databases and reference lists were searched from 2000 to 2013 using the key words
“Chlamydia trachomatis”, “population-based study” and “disease prevalence”. Reference lists were checked. Studies
were included in the analysis if Chlamydia trachomatis prevalence was reported for both men and women in a
population-based study. Prevalence rates for men and women were described as well as highest prevalence rate
by age and sex. The difference in prevalence between the sexes in each study was calculated.
Results: Twenty-five studies met the inclusion criteria and quality assessment for the review. In nine of the
twenty-five studies there was a statistically significant sex difference in the chlamydia prevalence. In all nine studies the
prevalence of chlamydia was higher in women than in men. The prevalence for women varied from 1.1% to 10.6%
and for men from 0.1% to 12.1%. The average chlamydia prevalence is highly variable between countries. The highest
prevalence of chlamydia occurred predominantly in younger age groups (< 25 years). The absence of symptoms in
population-based urogenital chlamydia infection is common in men and women (mean 88.5% versus 68.3%).
Conclusions: The urogenital chlamydia trachomatis prevalence in the general population is more similar than
dissimilar for men and women. A modest sex difference is apparent. The prevalence rates can be used to inform
chlamydia screening strategies in general practice.
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Background
Urogenital Chlamydia trachomatis represents one of
the most common bacterial sexually transmitted infections
(STIs) globally. The infection is mostly asymptomatic,
easily tested and single-dose treatments of oral antibiotics
are readily available [1]. Early diagnosis and treatment
are important to avoid transmission to partners and
to prevent complications. Left untreated it can have
significant and long-term complications, particularly
in women. These include pelvic inflammatory disease,
ectopic pregnancy, tubal factor infertility and chronic
pelvic pain [2,3]. The role for this pathogen in the
development of male epididymitis and orchitis is widely
accepted [4]. In (chronic) prostatitis the exact role is
still under debate because of the technical difficulties in
localizing Chlamydia trachomatis to the prostate [5].
Lack of patient knowledge about chlamydia and/or
the absence of symptoms of most chlamydia infections
means that two important stimuli for seeking health
care are absent [6-8]. Opportunistic screening is essential
if control of this infection is to be achieved. Although
there is an absence of evidence about the benefits of
opportunistic chlamydia screening in the general popula-
tion active case-finding for chlamydia is recommended
[2,9,10]. General practitioners (GPs) attend to the majority
of STI consultations and are the first point of contact
with the health care system for most individuals in
many countries and therefore ideally placed to screen
patients [11,12]. Prevalence studies in the general
population are important to investigate the occurrence
of chlamydia infections in the population served by
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GPs and can be used to guide the focus of screening
activities.
The research and screening is more focused on females,
with the burden of disease and infertility considered to
be a predominantly female problem [9,13]. For example,
annual screening for all sexually active women < 25 years
is recommend in the US for women and not for men
[14]. In many countries, women are more the target of
chlamydia screening in the general population, reducing
morbidity in women and not in men [10,15-17]. Emerging
evidence suggests also an effect of a chlamydia infection
on male fertility although more well-designed studies are
required to prove a causal factor of chlamydia infection
[4]. Women are more the focus of chlamydia control
activities because they have more contact with health
care related to sexual health i.e. cervix smear, oral
contraception, pregnancy and IUD insertion [18]. Also,
women have a higher uptake rate in chlamydia screening
programmes [19,20]. For example, in a register based
screening programme in the Netherlands, the participation
rate was significantly higher among women (21%) than
among men (10.4%) [21]. Last, in the literature, for various
reasons women are still more than men considered
biologically and psychosocially susceptible to chlamydia
infection [22,23].
Non-population-based systematic reviews have con-
sistently shown that the pooled prevalence of genital
chlamydia between males and females is similar [16,24,25].
A systematic review and meta-analysis conducted in
Australia found a pooled prevalence for women <
25 years of 5% (95 CI 3.1,6.9) and a pooled prevalence
for men < 30 years of 3.9% (95 CI 2.7,5.1) in community
and general practice settings. Most studies included in
these reviews do not compare men and women directly
in a community setting or do not report the data separately
[25]. The reviews also indicated important gaps of the
knowledge about chlamydia prevalence particularly in
men and in the general population. For example, in a
systematic review of prevalence studies in the United
Kingdom, only 11% of the reported prevalence esti-
mates were from males [24]. Asymptomatic men are
under-identified in these studies and they probably play
an important role in sustaining the transmission of
chlamydia in the population.
While Chlamydia trachomatis infection is an im-
portant public health issue for women, it is probably
not without importance for men. The need for robust
chlamydia estimates among women and men in the
general population are essential to help elucidate the
burden of infection. If required, GPs’ awareness of a
chlamydia infection and sensitivity for active case-finding
in both women and men should be increased. This
systematic review examines the available literature on
the prevalence of genital Chlamydia trachomatis infection
in the general population in studies that directly compare
men and women.
Methods
Search strategy
We performed a search of the literature in the electronic
bibliographic databases PubMed, Embase and CINAHL
for English-language articles published between January
1, 2000 and December 31, 2012. The following search
terms were used: “Chlamydia trachomatis” AND “preva-
lence” AND “population-based study OR population”.
Reference lists of included articles were checked for
potential studies. Also, the reference lists of selected
systematic reviews were hand-searched for further publi-
cations of interest [16,24,25]. A flow chart of the search is
shown in Figure 1.
Inclusion and exclusion criteria
Studies were eligible for inclusion in the review if they
(1) unambiguously reported prevalence of Chlamydia
trachomatis infection in the general population, (2) com-
pared and reported the chlamydia prevalence among
men and women, (3) reported data from a population
that was described as non-medical or non-health-care
setting, (4) used nucleic acid amplification tests (NAAT)
for diagnostic testing and (5) used a cross-sectional
study design. We excluded articles that (1) reported only
on men or women, (2) reported on selective populations,
for example commercial sex workers, soldiers, ethnic
groups, gynaecological patients or follow-up, (3) reported
on prevalence among individuals with urogenital symp-
toms and (4) used serology for diagnosis. The first
author (PD) applied the inclusion criteria to potentially
eligible studies.
Methodological assessment of reviewed studies
The studies were assessed and information extracted
by two authors independently (PD, DT). Disagreements
were resolved by discussion and consensus with the
third author (TLJ). To assess the usefulness of the
prevalence studies four questions were required to be
answered affirmatively [26,27]: (1) is the problem being
studied in the general population with data obtained
from registers or data administrations independently
from a health care setting?; (2) Is the study’s sampling
design fully described?; (3) Was a probabilistic sample
used?; (4) Is prevalence broken down by sex? Further
assessment of the quality of the studies included the
response rate of the total sample and sex subgroups
(major flaw if < 40%), reporting number screened,
reporting of prevalence type and total prevalence,
prevalence in subgroups and precision of estimation
(95% CI, error) [26]. If necessary, authors were contacted
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by email for additional information for example the origin
of the registries or administration database [28,29].
The prevalence for both men and women, and if
available the highest prevalence rate by age and sex,
were extracted. We calculated the difference in prevalence
between the sexes for each study and its 95% confidence
intervals [30]. The data were not pooled for meta-analysis.
It was likely that there would be considerable hetero-
geneity between studies making any formal meta-analysis
less valid. Also, it was not considered important to
the interpretation of the data because of the different
geographical location of each study and therefore of
limited clinical added value of this pooled prevalence
rate to GPs.
Results
Description of included studies
Our literature searches identified 698 studies which were
screened by title and abstract. The full text of thirty-
seven articles was read and fourteen were excluded. Of
the remaining twenty-three articles the reference lists
were searched and we included seven additional studies.
Thirty studies were assessed for eligibility. Twenty-
five articles were included in the review. (Figure 1 and
Table 1).
The majority of the included studies were conducted
in the general community (18), three were conducted
in general practice [19,31,40] and four in schools
[35,42,46,51]. We included the studies that recruited
participants from general practices in the Netherlands
and the UK because in these countries the vast major-
ity of its population is registered at one general prac-
tice [53]. We included studies from Europe (13)
[19,28,29,31,32,38-40,44,47,49,51,52], the United States
of America (6) [34,35,41,42,45,50], Asia [36,46,48], Africa
[33], Australia [37] and the Caribbean [43].
Study sample sizes were moderate. The number of
individuals tested in each study varied considerably,
ranging between 123 and 7555 participants. In all studies
but two the number of female participants was higher
than male participants [28,33]. Most studies reported
95% confidence intervals for their prevalence rates of
chlamydia infection in men and women but only ten
studies conducted adequately statistically comparison of
prevalence rate by sex [28,33,35,36,38,39,43,45,49,50].
Also, the age groups chosen varied considerably, including
individuals at puberty or adolescence to adulthood
(minimum 12 years and maximum 67 years). The response
rates varied in men from 11.9% to 79.0% and in women
from 18.9% to 86.0%. Where reported, response rate in
all studies was higher for women than for men. Only
Result derived from search on 
PubMed (204), Embase (207) 
and CINAHL (287)
675 irrelevant articles excluded:  
- selective populations 113 
- accompanied by an intervention 6  
- only women or only men  180
- no prevalence study 319
- individuals with symptoms 49
- duplicates 4
- systematic reviews 4
698 studies screened by title 
and/ or abstract
23 articles met inclusion 
criteria and hand-searched for 
references
5 articles excluded: 
- no prevalence study 2
- no general population or unknown  2 
- study design not fully described 1
25 articles included in the 
review
30 full-text articles assessed 
for eligibility
7 references included
Figure 1 Flowchart of search, inclusions and exclusions from the systematic review.
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Table 1 Characteristics population-based studies reporting prevalence of Chlamydia trachomatis for both men and women
Authors (publication year) [Reference] Country Men tested Women tested Response rate Sampling Test M Test F Invitation Geographic area
Valkengoed (2000) [31] Netherlands 1908 2902 M 33.0% F 51.0% General practices PCR urine PCR urine By mail Urban
Fenton (2001) [32] UK 1474 2055 Total 71.0% General community LCR urine LCR urine By mail General population
Obasi (2001) [33] Tanzania 4749 4686 Total 80% General community PCR urine PCR urine By interviewer Rural
Turner(2002) [34] USA 244 335 Total 79.5% General community LCR urine LCR urine By interviewer Urban
Miller (2004) [35] USA 6767 7555 Total 87.6% Schools LCR urine LCR urine By interviewer Urban and rural
Joyee (2004) [36] India 603 841 NS General community PCR urine PCR urine By interviewer Urban and rural
Latif (2004) [37] Australia 525 694 M 43.1% F 56.9% General community PCR FVU PCR VVS By interviewer Rural
Klavs (2004) [29] Slovenia 683 764 M 50.9% F 60.0% General community PCR urine PCR urine By interviewer General population
Bergen (2005) [38] Netherlands 2930 5453 M 33.0% F 47.0% General community PCR urine PCR urine By mail Urban and rural
Götz (2005) [39] Netherlands 1999 4304 Total 41.0% General community PCR urine PCR urine By mail Urban and rural
Macleod (2005) [40] UK 1930 2801 M 26.6% F 36.4% General practices PCR urine PCR urine VVS By mail Urban and rural
Low (2007) [19] UK 1396 1869 M 29.5% F 39.5% General practices PCR urine PCR VVS By mail Urban
Deblina Datta (2007) [41] USA 3096 3536 Total 83.0% General community LCR urine LCR urine By interviewer General population
Stein (2008) [42] USA 5074 5854 Total 88.6% Schools LCR urine LCR urine By interviewer NS
Adams (2008) [43] Barbados 190 207 M 79.0% F 86.0% General community PCR urine PCR urine By interviewer NS
Uusküla (2008) [44] Estonia 215 345 M 32.0% F 48.0% General community PCR FVU PCR VVS By mail Urban and rural
Beydoun (2010) [45] USA 2447 3164 NS General community NAAT urine NAAT urine By interviewer NS
Imai (2010) [46] Japan 2595 4003 Total 81.5% Schools PCR urine PCR urine By interviewer NS
Goulet (2010) [47] France 1135 1445 M 65.0% F 71.0% General community PCR urine PCR VVS By interviewer Urban and rural
Parish (2011) [48] China 1138 1235 Total 69.0% General community LCR urine LCR urine By interviewer Urban and rural
Desai (2011) [28] Germany 952 855 NS General community NAAT urine NAAT urine NS General population
Bozicevic (2011) [49] Croatia 123 151 M 27.9% F 37.5% General community PCR urine PCR urine By interviewer Urban and rural
Eggleston (2011) [50] USA 798 1322 M 17.7% F 26.5% General community NAAT urine NAAT urine By interviewer Urban
Gravningen (2012) [51] Norway 466 565 M 28.8% F 34.9% Schools PCR FVU PCR FVU Class-wise Rural
Klovstad (2012) [52] Norway 605 930 M 11.9% F 18.9% General community NAAT FVU NAAT FVU By mail Urban and rural
NS: data not stated.
PCR: polymerase chain reaction.
LCR: ligase chain reaction.
FVU: first voided urine.
VVS: vulvovaginal swab.
NAAT: nucleic acid amplification technique for example, DBProbeTec amplified DNA assay and APTIMA Combo2 assay.
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eleven studies reported total response (31.5% to 88.6%)
[32-35,39,41,42,46,48,50,51]. In three studies the total
response rate or response rate for men and women
separately was below 40% (major flaw) [19,40,49]. In
four studies the response rate for men was below 40%
only [31,38,44,52]. Of the seven studies reporting low
participation rates, six studies invited participants by
mail [19,31,38,40,44,49,52].
The most commonly utilized sample was urine or first
voided urine for both men and women. First voided
urine samples were tested for all of the male population.
For women, in five studies a self-obtained lower vaginal
swab was used or offered [19,29,40,44,47]. The preva-
lence of symptoms was reported in only eight studies
[19,33,35,38,42-44,52].
Prevalence of chlamydia infection by sex
The reported prevalence of chlamydia infection among
men and women in population-based settings in various
countries was diverse, ranging from 0.1% to 12.1% in
men and from 1.1% to 10.6% in women. Table 2 shows
the prevalence of the included studies by sex and the
calculated difference in prevalence between the sexes
of each study. We found a statistically significant
difference in chlamydia prevalence in nine studies
[28,33-35,38,42,44,46,51]. The study characteristics of
these nine studies did not differ from the other studies
in terms of geographic area, number of participants
tested, age or response rate. Black women and men
were disproportionately affected. Three studies reported
particularly high chlamydia prevalence in black parti-
cipants compared to nonblack participants with rates
generally higher in women than in men [34,35,38]. For
example, Miller et al. found a chlamydia prevalence in
black men of 11.12% and in black women of 13.95%
compared to a prevalence in white men of 1.38% and in
white women of 2.52% [35].
In urban settings, chlamydia prevalence for women
ranged from 2.8-6.2% and for men from 1.6-5.3% (Table 2).
In rural settings, chlamydia prevalence for women
ranged from 1.6-7.3% and for men from 1.0-3.9%.
Prevalence rate for women was highest in a study with
participants aged 15–20 years. Ten studies reported on
chlamydia prevalence estimates from studies conducted
in rural and urban settings. Chlamydia prevalence for
women ranged from 1.1-6.9% and for men from 1.2-
7.3%. Highest prevalence rates in women and men were
in studies with predominantly adolescents and small
sample sizes.
The five studies that used self-obtained vaginal swabs
in women and first voided urine in men, found no sta-
tistically significant difference in chlamydia prevalence
in men and women (Table 2) [19,37,40,44,47]. Reported
prevalence estimates were 1.6–6.9% for women and
1.4–5.3% for men. In sixteen studies first voided urine
was used in both women and men as test specimen. In
these studies, chlamydia prevalence in women ranged
from 1.1-10.6% and in men from 0.1-12.1%.
Prevalence of chlamydia infection by sex and age group
Age-specific rates of chlamydia prevalence were reported
in fourteen studies (Table 3) [29,31-33,36,38,40-42,45,
47,48,51,52]. Unfortunately, the reporting of chlamydia
prevalence among the different age groups was diverse and
the studies used variable age groups making comparison
between studies difficult. For example, not all studies
restricted age groups to cohorts of five years.
Overall, in both men and women young age groups
(<25 years) have higher chlamydia prevalence rates than
older age groups but chlamydia prevalence in young age
groups is not different for men and women. In six studies
the highest prevalence of chlamydia infection was in the
same age group for men and women [29,31,40,45,51,52].
In five studies women compared to men had the high-
est chlamydia prevalence at a younger age group
[32,36,38,41,47].
Furthermore, in all fourteen studies but two, the
highest chlamydia prevalence occurred among partici-
pants < 25 years of age; in women ranging from 2.1-
6.6% and in men from 1.0-6.3%. In two studies the
highest age group was > 25 years in both men and
women. One study, originated from India, reported
the highest chlamydia prevalence in men 31–45 years
of age and in women 31–35 years of age (2.1% versus
1.9%). In a study from China, the highest chlamydia
prevalence was found in men aged 25–34 years and in
women aged 35–44 years (3.9% versus 4.2%) [36,48].
The presence of symptoms by sex
There were eight studies that reported information on
the presence of symptoms among individuals tested
[19,33,35,38,42-44,52]. The absence of symptoms in
urogenital chlamydia infections varied in men from
73.9% to 94.6% and in women from 45.3% to 95.5%. In
all studies but one [35], the absence of symptoms was
higher in men than in women.
Discussion
Statement of the principal findings
In our systematic review of 25 studies, we found modest
sex differences in the prevalence of chlamydia infection
between men and women in the general population.
The prevalence for women varied from 1.1% to 10.6%
and for men from 0.1% to 12.1%. Nine out of twenty-five
studies showed a statistically significant higher prevalence
of chlamydia among women compared to men. The
majority of the included studies did not found a sex
difference. Where studies reported age-based estimates,
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younger participants had higher prevalence than older
participants but this is the case for both men and
women. Also, the prevalence of Chlamydia trachomatis
in urban and rural areas did not differ between men
and women. The review highlighted that chlamydia
prevalence was highly variable between countries but
with rates often as high in men as in women. The
commonly held assumption that chlamydia infection is
more prevalent in women than in men should therefore
be reconsidered.
Strengths and weaknesses of the study
Two methodological issues need to be addressed as they
may influenced the validity of these findings. Firstly,
the majority of the studies had low or unspecified par-
ticipation rates more for men than for women (< 60%).
A low participation rate can induce non-participation
bias and the population sample under study may not be
generalizable to the whole population [54]. Few studies
collected data on non-respondents for comparison with
respondernts to assess the implications of study non-
participation. It is uncertain how and if non-participation
bias influenced the results. Secondly, most studies used
first voided urine in women instead of vulvovaginal
swabs. Both specimens from women are suitable but the
vulvovaginal swab is the specimen of choice in women
[55]. The number of infections identified in women in the
studies using first voided urine may have been higher
when using a vulvovaginal swab. The sensitivity of first
voided urine for the detection of chlamydia infection in
women is lower than vaginal specimens. Last we did
not address specific ethnic backgrounds in our review.
Table 2 Results population-based studies reporting prevalence of Chlamydia trachomatis for both men and women
Authors (publication year)
[Reference]
Overall Men Women Prevalence difference
by sex (p or OR)
Calculated risk
difference by sex (M-F)
95% CI
% (95% CI) % (95% CI) % (95% CI)
Valkengoed (2000) [31] NS 2.4 (1.7-3.0) 2.8 (2.2-3.4) NS −0.4 −1.31 ; 0.51
Fenton (2001) [32] NS 2.2 (1.5-3.2) 1.5 (1.1-2.1) NS 0.7 −0.21 ; 1.62
Obasi (2001) [33] 1.8 (NS) 1.0 (0.8-1.4) 2.4 (2.3-2.9) OR 2.4 (NS) −1.4 −1.92 ; -0.88†
Turner(2002) [34] 3.0 (SE 0.8) 1.6 (NS) 4.3 (NS) NS −2.7 −5.38 ; -0.02†
Miller (2004) [35] 4.2 (3.5-4.9) 3.7 (2.9-4.6) 4.7 (3.9-5.7) OR 1.3(1.0-1.6) −1.0 −1.66 ; -0.34†
Joyee (2004) [36] 1.1 (0.5-1.7) 1.2 (0.4-2.0) 1.1 (0.5-1.7) P > 0.05 0.1 −1.02 ; 1.22
Latif (2004) [37] 9.6 (NS) 9.0 (NS) 10.0 (NS) NS −1.0 −4.02 ; 2.02
Klavs (2004) [29] NS 3.0 (1.9-4.6) 1.6 (1.0-2.7) NS 1.4 −0.33 ; 3.13
Bergen (2005) [38] 2.0 (1.7-2.3) 1.5 (1.1-1.9) 2.5 (2.0-3.0) P < 0.001 −1.0 −1.60 ; -0.39†
Götz (2005) [39] 2.4 (2.1-2.8) 2.0 (1.4-2.7) 2.6 (2.2-3.2) OR 1.4; P = 0.08 −0.6 −1.38 ; 0.18
Macleod (2005) [40] 3.0 (2.3-3.9) 2.8 (2.2-3.4) 3.6 (3.1-4.9) NS −0.8 −1.81 ; 0.21
Low (2007) [19] NS 5.3 (4.4-6.3) 6.2 (4.9-7.8) NS −0.9 −2.51 ; 0.71
Deblina Datta (2007) [41] 2.2 (1.8-2.8) 2.0 (1.6-2.5) 2.5 (1.8-3.4) NS −0.5 −1.21 ; 0.21
Stein (2008) [42] NS 3.9 (3.1-4.8) 5.1 (4.2-6.0) NS −1.2 −1.98 ; -0.43†
Adams (2008) [43] 11.3 (8.4-14.2) 12.1 (7.7-16.5) 10.6 (6.7-14.5) P = 0.643 1.5 −4.75 ; 7.75
Uusküla (2008) [44] 5.4 (3.0-7.5)* 2.7 (0.3-5.0)* 6.9 (3.6-10.3)* NS −4.2 −7.64 ; -0.76†
Beydoun (2010) [45] 1.6 (1.3-1.9) 1.7 (NS) 1.6 (NS) P = 0.8 0.1 −0.57 ; 0.77
Imai (2010) [46] NS 6.7 (NS) 9.5 (NS) NS −2.8 −4.12 ; -1.48†
Goulet (2010) [47] NS 1.4 (0.8-2.6) 1.6 (1.0-2.5) NS −0.2 −1.14 ; 0.74
Parish (2011) [48] NS 2.1 (1.3-3.3)* 2.6 (1.6-4.1)* NS −0.5 −1.72 ; 0.72
Desai (2011) [28] 0.9 (0.5-1.3) 0.1 (0.0-0.3) 1.8 (0.9-2.6) P < 0.001 −1.7 −2.61 ; -0.79†
Bozicevic (2011) [49] 6.2 (3.3-9.1) 7.3 (NS) 5.3 (NS) P = 0.491 2.0 −3.82 ; 7.82
Eggleston (2011) [50] 3.9 (2.8-5.0) 4.5 (2.4-6.5) 3.4 (2.2-4.6) OR 0.6; P = 0.16 1.1 −0.64 ; 2.84
Gravningen (2012) [51] 4.1 (3.3-5.3) 3.9 (2.3-6.0) 7.3 (5.3-9.7) NS −3.4 −6.17 ; -0.63†
Klovstad (2012) [52] 5.5 (4.5-6.8) 5.1 (3.8-6.8) 5.8 (4.5-6.8) NS −0.7 −3.01 ; 1.61
*: Prevalences after weighting for the population distribution.
†: statistically significant difference.
NS: Data not stated.
CI: 95% confidence interval.
SE: Standard error.
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Few studies presented chlamydia infection by ethnical
background. Ethnicity is a known risk factor for STIs
[34,35].
The strengths of this review are that, in our opinion,
it provides the most comprehensive review to date of
chlamydia prevalence estimates in the general population
directly comparing men and women. We conducted
comprehensive literature searches of multiple databases
and used rigorous methods to appraise the articles. It is
unlikely that we excluded important articles in this
field. All studies used the nucleic acid amplification test
with high sensitivity and specificity not only greatly
enhancing the acceptability of a screening intervention but
also increasing the reliability of the prevalence estimates. It
is the first review in this area to confirm the previous
conclusions in other systematic reviews of chlamydia
prevalence estimates in non-population-based studies
that the prevalence of urogenital chlamydia infections
is as high in men as in women [16,24,25].
Implications
It is clear from this review that men are also an important
reservoir of chlamydia infection for women and as such
men should also be targeted for chlamydial screening.
The vulnerability of women for a urogenital chlamydia
infection in different countries did not emerge as a
robust trend in this review of the literature. The reason
for the reported sex differences are explained in the
literature as artefacts or bias of reporting and the fact
that women are more studied and more tested than men
[16,24,25]. Chlamydia screening is frequently performed
in women even in the absence of symptoms for example
in routine gynaecologic care, Pap test, IUD insertion or
unintended pregnancy, and it is more common to perform
Table 3 Results population-based studies reporting prevalence of Chlamydia trachomatis for sex related to age
Authors (publication year)
[Reference]
Age group Highest prevalence
by age in men
Prevalence %
(95% CI)
Highest prevalence
by age in women
Prevalence %
(95% CI)
sex difference
by age
Valkengoed (2000) [31] 15-40 21-25 3.3 (1.0-5.5) 21-25 4.4 (2.6-6.3) ↔
Fenton (2001) [32] 18-44 25-34 3.0 (1.7-5.1) 18-24 3.0 (1.7-5.0) ↑
Obasi (2001) [33] 15-19 18 1.8 (1.0-2.8) 19 3.2 (2.2-4.5) ↓
Turner(2002) [34] 18-35 18-20* 8.0 (SE 3.9) 18-20* 8.0 (SE 3.9) -
Miller (2004) [35] 18-26 20-21* 4.7 (3.6-6.2) 20-21* 4.7 (3.6-6.2) -
Joyee (2004) [36] 15-45 31-45 2.1 (0.0-5.0) 31-35 1.9 (0.0-3.9) ↑
Latif (2004) [37] 18-49 ns ns -
Klavs (2004) [29] 13-67 18-24 4.1 (2.2-7.4) 18-24 4.1 (2.2-7.4) ↔
Bergen (2005) [38] 15-29 25-29 4.1 (2.1-6.2) 15-19 4.3 (1.5-7.0) ↑
Götz (2005) [39] 15-29 15-19* 3.1 15-19* 3.1 -
Macleod (2005) [40] 16-39 20-24 5.3 (4.4-6.3) 20-24 6.2 (4.9-7.8) ↔
Low (2007) [19] 16-24 ns ns -
Deblina Datta (2007) [41] 14-39 20-29 3.2 (2.4-4.3) 14-19 4.6 (3.7-5.8) ↑
Stein (2008) [42] 18-26 18-24 1.0 (0.6-1.5) 25-26 2.1 (1.3-3.5) ↓
Adams (2008) [43] 18-35 18-20* 19.8 18-20* 19.8 -
Uusküla (2008) [44] 18-35 ns ns -
Beydoun (2010) [45] 14-39 <25 2.7 (SE 0.6) <25 2.8 (SE 0.7) ↔
Imai (2010) [46] 18-39 20 8.3 19 12.2 -
Goulet (2010) [47] 18-44 25-29 2.7 (0.8-8.0) 18-24 3.6 (1.9-6.8) ↑
Parish (2011) [48] 20-64 25-34 3.9 (1.8-8.2) 35-44 4.2 (2.7-6.7) ↓
Desai (2011) [28] 12-17 ns 17 3.7 -
Bozicevic (2011) [49] 18-25 ns ns -
Eggleston (2011) [50] 15-35 15-19* 8.0 (4.3-11.6) 15-19* 8.0 (4.3-11.6) -
Gravningen (2012) [51] 15-20 19-20 7.1 19-20 11.1 ↔
Klovstad (2012) [52] 18-25 18-21 6.3 (3.9-10.0) 18-21 6.6 (4.7-9.3) ↔
*: Reported by age only, not age and sex.
ns: Data not stated.
↔: No sex difference in Chlamydia prevalence related to age.
↑: Chlamydia prevalence related to age highest in men.
↓: Chlamydia prevalence related to age highest in women.
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population-based chlamydia screening activities for women
[13,14]. By contrast, fewer men are diagnosed in primary
care: men are often treated for chlamydia without a
definitive diagnosis, based upon symptoms such as
urethritis or being a contact of a women with a chlamydia
infection [56,57]. Also this review shows that men con-
sistently have lower participation rates in chlamydia
prevalence studies. The results of this study confirm and
strongly support the need for higher coverage of men
in chlamydia screening and research activities [4,24].
The conclusion from this review is that the prevalence
of chlamydia infection in men and women in the general
population is more similar rather than dissimilar regardless
of age or level of urbanisation. According to the literature,
many factors shape women’s and men’s risks for chlamydia
infection differently [22,23,58]. Biological predisposition
and certain gender-specific behaviours are mentioned
in the literature as possible reasons for women being
more at risk for chlamydia and other STIs than men
[58,59]. For example, cervical ectopy, especially in young
women, may increase their susceptibility to chlamydia
infection. Cervical ectopy is more common in women
using oral contraceptives [60]. Hormonal contraceptives
are associated with an increased risk of chlamydia
infection [60-62]. Vaginal douching is associated with
bacterial vaginosis and HIV, both increasing the risk for
other STIs [63]. A direct association between douching
and chlamydia is less consistent [64]. In the male how-
ever, little is known about analogous phsysiological
changes that might affect a man’s risk of infection with
chlamydia. Circumcision in men, not in women, appears
to reduce the risk of acquiring STI [65]. Men tend dispro-
portionately to place monogamous women at risk for
STI [58]. All this may be true, in the general population
it seems to result in a modest difference in the prevalence
of chlamydia among men and women only.
Conclusion
We found modest sex differences in prevalence rates
amongst general populations but the prevalence of
chlamydia infection in men and women is more similar
than they are dissimilar. The prevalence of Chlamydia
trachomatis in population-based studies ranges from
0.1% to 12.1% in men and from 1.1% to 10.6% in
women depending upon age and country. The prevalence
rates can be used to inform chlamydia screening strategies
in general practice in men and women given that the
most serious long term consequence of chlamydia for
individual women, infertility, is one that will ultimately
affect also men.
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